(Q38067358)

28 August 2017

1 reference

title

Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease (English)

1 reference

28 August 2017

Max Christoph Liebau

1

0 references

author name string

Andreas Lucas Serra

series ordinal

2

1 reference

28 August 2017

language of work or name

1 reference

14 December 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

28

1 reference

28 August 2017

issue

9

1 reference

28 August 2017

page(s)

1771-1783

1 reference

Diagnosis and management of childhood polycystic kidney disease

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

When cilia go bad: cilia defects and ciliopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

The vertebrate primary cilium in development, homeostasis, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Centrioles, centrosomes, and cilia in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Autosomal Recessive Polycystic Kidney Disease: The Clinical Experience in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

The cytoplasmic tail of fibrocystin contains a ciliary targeting sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Polycystin-2 expression is regulated by a PC2-binding domain in the intracellular portion of fibrocystin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Kinesin-2 mediates physical and functional interactions between polycystin-2 and fibrocystin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Autosomal recessive polycystic kidney disease: radiologic-pathologic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Perinatal assessment of hereditary cystic renal diseases: the contribution of sonography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Renal cystic diseases: diverse phenotypes converge on the cilium/centrosome complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Autosomal recessive polycystic kidney disease: long-term outcome of neonatal survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Role of primary cilia in the pathogenesis of polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Bending the MDCK cell primary cilium increases intracellular calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Diagnostic approach in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Why kidneys fail in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Cystic and inherited kidney diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Clinical spectrum and pathogenesis of nephronophthisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Renal cystic diseases in children: new concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Simple renal cysts in children: diagnosis and follow-up with US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Unified criteria for ultrasonographic diagnosis of ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Imaging approaches to patients with polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

The incidence of simple renal cyst by computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Ciliopathies: an expanding disease spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Magnetic resonance imaging of kidney and cyst volume in children with ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Progression of autosomal-dominant polycystic kidney disease in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Determinants of renal volume in autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Evidence of extraordinary growth in the progressive enlargement of renal cysts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Prospective change in renal volume and function in children with ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Mutations in multiple PKD genes may explain early and severe polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Autosomal dominant polycystic kidney disease: the last 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Advances in the pathogenesis and treatment of polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Analysis of baseline parameters in the HALT polycystic kidney disease trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Sirolimus therapy to halt the progression of ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Everolimus in patients with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

mTOR inhibitors in polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Inhibition of MTOR disrupts autophagic flux in podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Role of mTOR in podocyte function and diabetic nephropathy in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-012-2370-Y

Early manifestations of polycystic kidney disease

21 January 2018

1 reference

12 December 2020

Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease

1 reference

12 December 2020

Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease

1 reference

12 December 2020

Hereditary polycystic kidney diseases in children: changing sonographic patterns through childhood

1 reference

12 December 2020

Polycystin-1 and -2 Dosage Regulates Pressure Sensing

1 reference

12 December 2020

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study

1 reference

12 December 2020

Genotype–phenotype correlations in fetuses and neonates with autosomal recessive polycystic kidney disease

1 reference

12 December 2020

Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease

1 reference

12 December 2020

Autosomal recessive polycystic kidney disease

1 reference

12 December 2020

Prognosis of autosomal dominant polycystic kidney disease diagnosed in utero or at birth

1 reference

12 December 2020

Autosomal recessive polycystic kidney disease: outcomes from a single-center experience.

1 reference

12 December 2020

Autosomal dominant polycystic kidney disease

1 reference

12 December 2020

Renal ultrasonographic evaluation in children at risk of autosomal dominant polycystic kidney disease

1 reference

12 December 2020

Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease

1 reference

12 December 2020

Volume progression in polycystic kidney disease

1 reference

12 December 2020

Aging and simple cysts of the kidney

1 reference

12 December 2020

Rapid MR imaging detection of renal cysts: age-based standards

1 reference

12 December 2020

Ovarian toxicity from sirolimus

1 reference

12 December 2020

10.1007/S00467-012-2370-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1038432920

0 references

1 reference